Lyrica pregabalin: Phase III data

Top-line data from the 11-week, double-blind, Chinese Phase III A0081265 trial in about 626 patients with painful DPN showed that once-daily 300 mg Lyrica missed the primary endpoint of improving mean pain score on a 0-10 point NRS vs. placebo (reduction relative to placebo of 0.28 points, p=0.0559). Lyrica is approved in China to treat postherpetic neuralgia (PHN). ...